fbpx
  • Home
  • Study Details
Open

Investigating whether TOL-3021 can stop autoimmune pancreatic beta cell attack in adults with recently diagnosed Type I Diabetes

This study investigates whether TOL-3021 can stop the autoimmune pancreatic beta cell attack in adults with recently diagnosed Type I Diabetes.

Age & Gender

  • 18 years ~ 40 years
  • Male, Female

Location

North Carolina (Statewide)

Incentives

$100 gift card per completed clinic visit

In-person visits : 22
Total length of participation : 42 months

Looking for Specific Volunteers

Able to participate:

  • Diagnosed with Type I Diabetes within last 5 years
  • Hemoglobin A1c level <7.6%
  • On insulin therapy
  • Willing to wear Dexcom G6 continuous glucose monitoring device throughout trial

Not eligible if:

  • BMI over 32
  • Pregnant or breastfeeding
  • Previous immunotherapy for T1DM
  • Liver disease, kidney disease, cardiac disease, or history of adrenal insufficiency
  • History of organ transplant including beta cell transplant

Contact the Team

Visit Location

100% Remote (online, phone, text)

Additional Study Information

Principal Investigator

John Buse
Medicine-Endocrinology

Study Topics

Diabetes
Immune System/Infections

IRB Number

19-1181

logo for the North Carolina Translational and Clinical Sciences Institute
logo for UNC Health
logo for UNC School of Medicine
logo for UNC Research
Research for Me logo

Copyright © 2013-2020 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH.  This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Questions?

  • This email address is being protected from spambots. You need JavaScript enabled to view it.